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UV-induced DNA lesions and nucleotide excision repair 
Ultraviolet (UV) light induces DNA photolesions such as cyclobutane 
pyrimidine dimer (CPD) and (6-4) photoproduct (6-4PP), and causes cell death, 
mutation and neoplastic transformation.  Nucleotide excision repair (NER) is a 
versatile repair system that removes a variety of helix-distorting DNA lesions from the 
genome and UV-induced DNA photolesions are repaired by this repair system in 
humans (Hoeijmakers, 2001; Friedberg et al., 2006).  NER deals with not only DNA 
photolesions but also chemical-induced bulky base adducts.  Defects in the NER 
pathway give rise to an autosomal recessive disease, xeroderma pigmentosum (XP), 
which is classified into seven complementation groups, XP-A through XP-G, based on 
which NER gene is mutated (Friedberg et al., 2006).  XP patients are characterized 
mainly by photosensitivity, pigment changes and a predisposition to skin cancer on 
sun-exposed area, which are possibly caused by the accumulation of UV photolesions 
in epidermal cells (Cleaver et al., 1989).  Human skin consists of epidermal and 
dermal components, and keratinocytes and melanocytes in the epidermis are major 
targets for solar UV.  Keratinocytes change their morphology and gene expression 
during the process of terminal differentiation in which they migrate from a 
proliferative basal cell layer to upper nonreplicating layers.  In most of in vitro study, 
however, dermal fibroblasts have been often used, since they can grow easily in 
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standard culture medium containing serum and maintain their growth activity for 
longer periods, compared with epidermal keratinocytes and melanocytes. 
 
Current model for the molecular mechanism of NER  
NER reaction consists of two sub-pathways with different damage 
recognition steps.  DNA lesions induced in transcriptionally inactive DNA regions or 
the non-transcribed strand of expressed genes are recognized by 
XPC-RAD23B-centrin2, in cooperation with DDB1-DDB2 (called DDB or UV-DDB) 
complex especially for CPD, and repaired by a global genome repair (GGR) 
sub-pathway.  In contrast, those in the transcribed strand of expressed genes are 
recognized by stalled RNA polymerase II, in concert with CSA and CSB proteins, and 
repaired by a transcription-coupled repair (TCR) sub-pathway.   
Following either damage recognition step, common NER factors including 
TFIIH, XPA, RPA, XPG and XPF-ERCC1 are recruited in a step-by-step manner.  
The ten-subunit complex TFIIH containing XPB and XPD subunits is recruited 
through its interaction with XPC (Araujo et al., 2001; Li et al., 1998; Yokoi et al., 
2000) and unwinds DNA around the lesion using their ATPase-dependent helicase 
activity (Schaeffer et al., 1993; 1994).  The TFIIH-generated open DNA structure 
induces the recruitment of the other NER factors, XPA, RPA and XPG (Evans et al., 
1997; Mu et al., 1997).  XPA binds to damaged DNA (Robins et al., 1991; Jones and 
Wood, 1993) as well as kinked DNA (Camenisch et al., 2006), suggesting its 
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implication in a damage verification step rather than in an the initial damage 
recognition step.  RPA is a trimeric protein with high affinity for single strand DNA 
and stabilizes the opened DNA structure, protecting undamaged single-stranded 
regions.  XPG is known as a structure-specific endonuclease that makes a 3’ incision 
(Matsunaga et al., 1995) and seems to be recruited to damaged sites through its 
interaction with TFIIH (Zotter et al., 2006).  The last factor to join the preincision 
complex is XPF-ERCC1, the second endonuclease making 5’ incision (Sijbers et al., 
1996), which is recruited by XPA (Li et al., 1994).  A dual incision is finally 
accomplished by XPG and XPF-ERCC1 in a well-concerted manner and excises a 
~28-mer fragment bracketing a DNA lesion (Staresincic et al., 2009; Matsunaga et al., 
1995).  To complete the NER reaction, the resultant single-stranded DNA gaps are 
filled by DNA polymerase δ, ε, or κ with aids of their accessory proteins (Aboussekhra 
et al., 1995; Araujo et al., 2000; Ogi et al., 2006) and sealed by DNA ligases (Moser et 
al., 2007).  The core NER reaction has been reconstituted in vitro with purified 

















However, NER reaction in vivo is much more complex especially in the 
chromatin context and is also regulated in transcriptional as well as post-translational 
mechanisms (Liu et al., 2010).  It has been shown that the tumor suppressor, p33ING 
enhances NER by increasing H4 acetylation, chromatin relaxation and the recruitment 
of XPA to CPD (Wang et al., 2006; Kuo et al., 2007).  Recent study has demonstrated 
that GCN5 histone acetyltransferase is recruited to DNA damage by E2F1 transcription 
factor and stimulates NER by promoting H3K9 acetylation (Guo et al., 2010).  
Futhermore, it has been reported that ATP-dependent chromatin remodeling complex, 
SWI/SNF enhances NER in the nucleosome core region in vitro and the remodeling 
activity of SWI/SNF depends on the presence of XPC, RPA and XPA (Hara et al., 
2002 & 2003; Zhao et al., 2009).  In addition, the E3 ubiquitin ligase complex has 
been reported to ubiquitinate histones H2A (Kapetanaki et al., 2006), H3 and H4 
Figure 1.  Model for the multistep process of GGR sub-pathway of NER 





















(Wang et al., 2006) and weaken their interaction with DNA, thereby facilitating the 
accessibility of repair proteins to damaged DNA.  The E3 ligase RNF8 and E2 
ubiquitin-conjugating enzyme Ubc13 are also involved in NER-dependent H2A 
ubiquitination (Marteijn et al., 2009).   
Post-translational regulation of NER reaction has been recently reported 
from various laboratories.  DDB heterodimer was found to form an E3 ubiquitin 
ligase complex with Cullin4A (Cul4A) and Roc1 (Groisman et al., 2003), and DDB1 
and DDB2 subunits function as an adaptor and a substrate receptor, respectively.  The 
Cul4A-Roc1-DDB1DDB2 E3 ligase complex relocates to damaged subnuclear regions 
and polyubiquitinate XPC and even DDB2, leading to the alteration of DNA binding 
properties of XPC-RAD23B and DDB and the proteasomal degradation of DDB2 
(Sugasawa et al., 2005).  This polyubiquitination appears to be required for cell-free 
NER reaction when DDB is bound to 6-4PP.  NER is also known to be regulated by 
acetylation and phosphorylation of NER factors as well.  It has been reported that 
XPA is phosphorylated by checkpoint kinase ATR after UV irradiation (Wu et al., 
2006).  Furthermore, a recent study showed that SIRT1, an NAD+-dependent histone 
deacetylase plays a positive role in UV-induced NER pathway through its binding to 
XPA and maintaining XPA in a hypoacetylated state (Fan and Luo, 2010), although a 
controversial result has been reported by other group (Kang et al., 2011).  From these 
observations, it is clear that NER reaction is highly regulated within a cell, but its 
whole picture still remains to be fully understood. 
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Assays for analyzing the induction and repair of UV photolesions 
A variety of techniques have been developed for detecting UV photolesions, 
and immunoassays using antibodies against CPD or 6-4PP, including an 
enzyme-linked immunosorbent assay (ELISA) (Wani et al., 1984; Matsunaga et al., 
1990) and immunoslot-blot assay (ISBA) (Wani et al., 1987; Vink et al., 1994), have 
been widely used these days.  The ELISA and ISBA are sensitive and quantitative, 
but somehow laborious and time-consuming due to experimental steps of genomic 
DNA extraction and its immobilization to 96-well microtiter plates or nitrocellulose 
membranes.  Accordingly, these assays require a large number of cells and are not 
suitable for NER analysis using poorly growing primary cells or multiple samples such 
as high throughput screening.  On the other hand, an in situ assay with 
immunofluorescence staining (Mori et al., 1989; 1990) omits the DNA extraction step 
and needs only a small number of cells, although the quantification of stained cells 
under a fluorescence microscope is also laborious and relatively less quantitative.  
The repair kinetics obtained by these assays reflects the activity of GGR sub-pathway 
of NER, since most of UV photolesions in the genome are removed by this 
sub-pathway.  In contrast, a conceptually different assay called host cell reactivation 
(HCR) reflects the activity of TCR sub-pathway.  This assay is based on the 
transfection of UV-irradiated plasmid containing a reporter gene (e.g. luciferase) into 
cells and the measurement of enzymatic activity of the gene products.  Though a 
 8 
number of other assay systems have been developed, there are no assays suitable for 












Anti-cancer chemotherapy and NER 
Anti-cancer drugs are grouped mainly into 4 categories such as 
chemotherapy, hormonal therapy, immunotherapy and molecular targeted therapy.  
Cisplatin is one of the most widely used and effective chemotherapeutic drugs and 
produces base adducts consisting of more than 90% intrastrand DNA crosslinks and 
less than 5% interstrand DNA crosslinks (Jung and Lippard, 2007; Koberle et al., 
2011), which are excised from the genome by NER and interstrand crosslink repair, 
respectively.  The effective treatment with cisplatin is limited due to the development 
Figure 2.  Conventional immunoassays for detecting CPD and 6-4PP 
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of resistant cells, which can be caused by alterations in drug transport, cytoplasmic 
drug detoxification, DNA repair activity and apoptosis pathway (Koberle et al., 2011).  
Since more than 90% of DNA damage induced by cisplatin is repaired by NER, the 
relationship between NER and cisplatin resistance has been studied for many years.  
The previous studies reported that some of cisplatin-resistant ovarian cancer cells 
exhibit more efficient repair of cisplatin-induced DNA damage (Matsuda et al., 1988; 
Parker et al., 1991), although a recent report showed that NER efficiency to remove 
cisplatin-induced DNA intrastrand crosslinks does not always correlates with cisplatin 
resistance in ovarian cancer cells (Wang et al., 2011).  
 
Objective of this study 
In this study, I tried to develop a microplate-formatted cell-based 
immunoassay, using an indirect immunofluorescence staining with lesion-specific 
antibodies combined with an infrared imaging system, which enables us to not only 
measure NER ability in various primary cells rapidly and quantitatively, but also apply 
to a screening system for drugs that inhibit or stimulate NER reaction.  Furthermore, 
in order to find new NER players and understand the molecular mechanism of cellular 
NER reaction, I tried to identify low molecular weight compounds affecting human 
NER by using the newly developed assay as well as the chemical library from the 
RIKEN natural product depository (NPDepo).  
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MATERIALS AND METHODS 
 
Cell lines and culture   
Human primary fibroblasts (NHDF) from different donors were purchased from 
Kurabo Industries (Osaka).  SuSa/T-n and XP3OS/T-n cells immortalized by 
introducing the human telomerase reverse transcriptase (hTERT) gene were provided 
by Dr. Kanji Ishizaki.  WI38VA13/3xFLAG-DDB2 cells were generated by 
introducing pcDNA-3xFlagDDB2 plasmid into SV40-transformed fibroblast line 
WI38VA13 in our laboratory.  The fibroblast lines and HeLa cells were cultured in 
Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% fetal bovine 
serum (Sigma) and 50 µg/ml gentamicin at 37oC in a humidified incubator under 5% 
CO2.  Human primary keratinocytes were obtained from Kurabo or DS Pharma 
Biomedical Co. (Osaka), and cultured in serum-free media from respective suppliers at 
37oC in a humidified incubator under 5% CO2.  Human primary melanocytes NHEM 
(Kurabo) were cultured in Medium254 supplemented with HMGS (Kurabo) at 37oC in 
a humidified incubator under 5% CO2.  KKLS cells, a stomach carcinoma cell line, 
were obtained from Dr. Yoshio Endo (Cancer Research Institute of Kanazawa 
University) and cultured in RPMI 1640 medium (Sigma) supplemented with 10% 
heat-inactivated fetal bovine serum (Sigma) and 50 µg/ml gentamicin at 37oC in a 
humidified incubator under 5% CO2.   
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Microplate-formatted cell-based immunoassay for NER of UV photoproducts 
(M-CINUP)   
Appropriate numbers of cells were inoculated in 96-well microplates and incubated for 
2 days to make them confluent, which suppresses cell division undesirable in this assay.  
Cells were washed twice with Dulbecco’s phosphate-buffered saline (-) (PBS (-)) and 
uniformly exposed to UV-B from health lamps (Toshiba, FL20SE) through a bottom 
side of the microplate.  The cells were fixed in methanol/acetone (1:1) at –20oC for 10 
min immediately or after various repair periods and treated with 2 M HCl for 30 min to 
denature cellular DNA.  After blocking non-specific antibody-binding sites with 1% 
nonfat dry milk in 10 mM PBS (pH 7.4), cells were stained with TDM-2 antibody 
specific for CPD or 64M-5 antibody specific for 6-4PP (Mori et al., 1991).  The 
binding of these antibodies to each photolesion was detected with biotin-labeled 
F(ab’)2 fragment of goat anti-mouse IgG (H+L) (Zymed) or biotin-labeled affinity 
purified antibody to mouse IgG (H+L) (KPL) and IRDye 800CW-labeled streptavidin 
(LI-COR).  The cells were counterstained with Sapphire700 (LI-COR), a non-specific 
cell stain for both the nucleus and cytoplasm of fixed cells.  Finally, two-color 
fluorescence intensity of each well was measured at 700 and 800 nm with the Odyssey 
infrared imaging system (LI-COR).  
 
Chemical library screening using M-CINUP 
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An authentic library (80 products) and a pilot library (376 products) were provided by 
RIKEN NPDepo.  The derivatives of active compound #8 were obtained from 
NPDepo or purchased from Namiki Shoji Co. (Tokyo).  Other compounds were 
kindly synthesized in the laboratory of Bioorganic Chemistry (Prof. Munetaka 
Kunishima, Kanazawa University). 
HeLa cells were inoculated at 3 x 104 per well in 3 sets of 96-well microplates and 
pretreated with each compound in duplicate (21 compounds per plate) after 2-day 
incubation.  The cells were irradiated with UV-B as described above and fixed 
immediately or after 1-h or 2-h repair period in the presence of each compound.  The 
repair kinetics of 6-4PP was analyzed by M-CINUP and compared with those in 
control cells treated with DMSO.   
 
Enzyme-linked immunosorbent assay (ELISA)   
SuSa/T-n cells cultured in 96-well microplates were irradiated with UV-B as described 
above and incubated for various periods.  In other experiments, KKLS cells cultured 
in 60-mm dishes were irradiated with 10 J/m2 of UV-C from germicidal lamps 
(Toshiba, GL-10) and incubated for various periods.  Genomic DNAs were purified 
with the DNeasy kit (Qiagen), and the amounts of CPD and 6-4PP were measured 
using TDM-2 and 64M-5 antibodies as described previously (Mori et al., 1991; 
Matsumoto et al., 2007). 
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Colony formation assay 
To investigate the toxicity of NPD13405, KKLS cells were seeded on 60-mm dishes 
(200 cells/dish) and various concentrations of NPD13405 were added following 6-h 
incubation.  The cells were incubated at 37 oC in a humidified incubator under 5% 
CO2 for 7 - 8 days, and colonies were counted after fixation with 99% ethanol and 
staining with Giemsa solution (Wako). 
For analyzing the effect of NPD13405 on the sensitivity to UV or anti-cancer drugs, 
KKLS cells were cultured in the presence or absence (DMSO only) of NPD13405 
(final 10 µg/ml) for 12 h and re-seeded on 60-mm dishes (200 cells/dish).  After 
incubation for 6 h, the cells were irradiated with various doses of UV-C or treated with 
cisplatin for 24 h or etoposide for 6 h with or without NPD13405.  After medium 
change, cells were incubated for 7 - 8 days and colonies were counted after fixation 
and staining as described above. 
 
Cell cycle analysis 
KKLS cells were incubated with 10 or 20 µg/ml of NPD13405 for 12 or 24 h and fixed 
in 99% ethanol at -20℃ after harvest.  After washing with FACS buffer (PBS 
containing 0.1% bovine serum albumin and 2 mM EDTA), cells were treated with 50 
µg/ml RNase A (Sigma) in FACS buffer for 30 min at 37℃ and stained with 25 µg/ml 
propidium iodide (PI) (Sigma).  The samples were analyzed using FACSCalibur and 
Cell Quest Pro software (BD Biosciences), and cell cycle distribution was determined 
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Establishment of a microplate-formatted cell-based immunoassay for rapid 
analysis of nucleotide excision repair ability 
Although various immunoassays using monoclonal antibodies against CPD 
and 6-4PP have been developed, there are no quantitative assays capable of evaluating 
their repair kinetics rapidly and easily using a small number of cells and further 
applicable to high through-put analyses using chemical or siRNA library.  In order to 
develop this type of assay, I introduced a cell-based immunoassay using 96-well 
microplates and combined it with an infrared laser imaging system to reduce 
background fluorescence and increase sensitivity.  CPD and 6-4PP induced in 
UV-B-irradiated cells are detected by indirect immunofluorescence staining with 
damage-specific monoclonal antibodies and quantitated by measuring whole 
fluorescence intensity in each well (Fig. 3).  During its development, two major 
potential problems were carefully considered.  First, well-to-well variation of the 
number of attached cells, possibly generated by inaccurate cell inoculation, cell death 
induced by UV irradiation, cell detachment by repeated washing steps during 
immunostaining and so on, was corrected by normalizing with a non-specific cell stain 
reagent, Sapphire700.  Second, in repair kinetics analysis, mitotic cell division, which 
diluted out photolesions in the cells, was minimized by optimizing inoculum size in 
each cell type to obtain a confluent state upon the assay. 
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I firstly tested the relationship between UV-B dose and infrared fluorescence 
intensity in the cell-based immunoassay.  Human SuSa/T-n cells were inoculated at 5 
x 103 or 1 x 104 per well and exposed to UV-B after 2 days.  Since UV-B exposure 
was conducted from a bottom side of microplate, I could not measure actual UV-B 
doses by UV dosimeter.  Therefore, I decided to compare the induction levels of CPD 
and 6-4PP under this exposure condition with those in UV-C-irradiated cells using 
ELISA (data not shown) and to express UV-B doses as “UV-C dose equivalents” in 
this study.  As shown in Figs. 4A and 4B, the wells exposed to UV-B exhibited strong 
fluorescence at 800 nm in a dose-dependent manner, although weak fluorescence is 
detectable in non-exposed wells as a background.  On the other hand, the 
fluorescence intensity at 700 nm, derived from sapphire700-stained cells, is dependent 
3 wells (96-well plate) !
/ each sample!
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Figure 3.  Newly developed microplate-fortatted cell-based immunoassay for NER of UV 
photoproducts (M-CINUP) 
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on their inoculum size, but not on UV-B doses (Fig. 4A).  Importantly, dose response 
curves from normalized values (800-nm intensity/700-nm intensity) were completely 
overlapped regardless of inoculum size and showed a linear increase up to 10 J/m2 
(CPD) and 40 J/m2 (6-4PP) of UV-C dose equivalents (Fig. 4C), demonstrating that 
sapphire700 staining is effective for the correction of well-to-well variation of cell 
number.   
 

















Figure 4.  Detection of CPD and 6-4PP in human SuSa/T-n cells by a cell-based immunoassay.  SuSa/T-n 
cells were inoculated at 5 x 103 (closed triangles) or 1 x 104 (closed circles) per well in 96-well microplates and 
incubated for 2 days.  The cells were irradiated with UV-B at the indicated doses (UV-C dose equivalents) and 
processed for detecting CPD and 6-4PP with TDM-2 and 64M-5 antibodies, respectively.  (A) Scanning images at 
700 nm (Sapphire700) and 800 nm (CPD or 6-4PP) were obtained by the Odyssey infrared imaging system.  (B) 
The 800-nm fluorescence intensity of each well was quantitated using the imaging system and attached software, 
and the mean values of each sample were calculated from sextuplicated wells.  Bars indicate the SD.  (C) 
Normalized values were calculated by dividing the 800-nm fluorescence intensity of each well by their respective 
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human cells.  NER-proficient SuSa/T-n or NER-deficient XP3OS/T-n (XP-A) cells 
were exposed to UV-B at 10 J/m2 of UV-C dose equivalent and fixed immediately or 
after 8- or 24-h incubation for CPD, whereas 40 J/m2 of UV-C dose equivalent and 4- 
or 8-h incubation were used for 6-4PP.  As a comparison, genomic DNA was 
extracted from SuSa/T-n cells exposed to UV-B under the same conditions and 
analyzed by a conventional ELISA.  In NER-proficient SuSa/T-n cells, 800-nm 
fluorescence was decreased with increasing repair periods (data not shown) and 
quantitative data exhibited similar repair kinetics to that obtained with ELISA (Fig. 5).  
In contrast, NER-deficient XP3OS/T-n cells showed no or little removal of CPD and 
6-4PP.  Taken together, I concluded that this assay is useful for rapid measurement of 
cellular NER activity with a relatively small number of cells and designated it as a 
microplate-formatted cell-based immunoassay for NER of UV photoproducts 
(M-CINUP).   
Figure 5.  Repair kinetics of CPD and 6-4PP in human SuSa/T-n and XP3OS/T-n cells.  
NER-proficient SuSa/T-n (closed circles) or NER-deficient XP3OS/T-n (closed triangles) cells were 
inoculated at 1 x 104 per well in 96-well microplates and irradiated with UV-B at 10 J/m2 (CPD) or 40 J/m2 
(6-4PP) of UV-C dose equivalent after 2-day incubation.  The cells were incubated for the indicated 
periods and processed for the detection of CPD and 6-4PP with a cell-based immunoassay.  Broken lines 
indicate the repair kinetics determined by ELISA.  Each point represents the mean of three independent 
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Analysis of the repair kinatics of CPD and 6-4PP in various primary cells from 
human skin 
Taking advantage of the M-CINUP, I examined the repair kinetics of CPD 
and 6-4PP in various primary cells from human skin.  Primary fibroblasts from a 
newborn and two adults aged 56 and 57 were tested within a single microplate and 
showed similar repair kinetics (Fig. 6A), consistent with the previous reports (Merkle 
et al., 2004; Takahashi et al., 2005).  I further examined the NER activity of 
keratinocytes and melanocytes from human epidermal layer, which is a primary target 
for solar UV exposure.  Because of their different cell shapes and smaller size 
compared with fibroblasts, I optimized their inoculum number being 3.5 x 104 
cells/well for keratinocytes and 8 x 104 cells/well for melanocytes.  Under these 
conditions, dose-dependent induction curves of CPD and 6-4PP were saturated at 
lower UV doses due to higher cell density (data not shown), letting me to use 5 J/m2 
and 20 J/m2 UV-C dose equivalents, respectively, for their repair analysis.  As shown 
in Fig. 6B, the repair kinetics of both photolesions exhibited no significant differences 








Keratinocytes in epidermis forms an environmental barrier by means of a 
special program of terminal differentiation, in which these cells migrate from a 
proliferative basal layer to upper nonreplicating layers with changing their shape from 
cuboidal to flatter one.  It is well known that keratinocytes in culture also easily 
differentiate by adding calcium ions.  Using the in vitro differentiation model system, 
I tested an impact of differentiation on cellular NER activity.  Keratinocyte 
Figure 6.  Repair kinetics of CPD and 6-4PP in various primary cells from human skin.  (A) Human 
primary fibroblasts from a newborn (closed circles) and adults aged 56 (closed triangles) and 57 (closed 
squares) were inoculated at 1 x 104 per well in 96-well microplates.  After 2 day-incubation, cells were 
irradiated and analyzed as described in the legend of Fig. 5.  (B) Human primary keratinocytes (closed circles) 
or melanocytes (open triangles) from newborn donors were inoculated at 3.5 x 104 or 8 x 104 per well, 
respectively, and incubated for 2 or 3 days.  The cells were irradiated with UV-B at 5 J/m2 or 20 J/m2 of UV-C 
dose equivalent and analyzed for the repair kinetics of CPD or 6-4PP, respectively.  Each point represents the 
































































differentiation was monitored by growth activity, cell morphology and the cellular 
level of a cross-linked form of involucrin, one of well-characterized differentiation 
markers (Rice et al., 1979), after the addition of calcium chloride at a final 
concentration of 1.5 mM.  Cell growth activity was significantly reduced (Fig. 7A) 
and the proportion of S-phase cells determined by BrdU incorporation was decreased 
(data not shown).  Cell morphology was changed from cuboidal to flatter one with the 
enforcement of cell-cell contacts (Fig. 7C).  In addition, immunoblotting revealed that 
a cross-linked form of involucrin (~140 kDa) was dramatically increased (Fig. 7B).  
These all results suggest that keratinocytes differentiate in vitro under this condition.  
To analyze NER efficiency in differentiated keratinocytes, growing keratinocytes were 
inoculated at 2.5 x 104 or 3.5 x 104 per well and cultured in the absence or presence of 
additional 1.5 mM calcium chloride for 3 days.  As shown in Fig. 7D, the repair 
kinetics of CPD and 6-4PP in differentiated keratinocytes was similar to that in 
undifferentiated ones, suggesting that differentiation has no significant impacts on 










Evaluation of drugs affecting NER efficiency using M-CINUP 
This new microplate-formatted assay is possibly applicable to rapid 
screening of chemicals that affect cellular NER activity.  To test this possibility, I 
evaluated the effects of MG132 and sodium butyrate on the repair kinetics of CPD and 
6-4PP in HeLa cells using M-CINUP.  MG132 is a proteasome inhibitor and has been 
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Figure 7.  Repair kinetics of CPD and 6-4PP in differentiated and undifferentiated keratinocytes.  (A and B) 
Human primary keratinocytes from a 33 year-old donor were inoculated at 1 x 105 in 35-mm plastic dishes and 
grown in culture medium with (closed circles) or without (open circles) additional 1.5 mM calcium chloride.  After 
incubation for the indicated periods, cells were harvested and counted (A).  The rest of harvested cells were lysed 
and analyzed by immunoblotting with anti-involucrin or anti-GAPDH antibody (B).  (C) Human keratinocytes were 
incubated in culture medium with or without additional 1.5 mM calcium chloride for 3 days and observed under a 
phase-contrast microscope.  (D) Human primary keratinocytes from a 33 year-old donor were inoculated at 3.5 x 
104 (circles) or 2.5 x 104 (triangles) per well in 96-well microplates and grown in culture medium with (closed 
symbols) or without (open symbols) additional 1.5 mM calcium chloride for 3 days.  The cells were irradiated with 
UV-B at 5 J/m2 or 30 J/m2 of UV-C dose equivalent and analyzed for the repair kinetics of CPD or 6-4PP, 
respectively.  Each point represents the mean of three experiments and bars indicate the SD. 
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butyrate is a histone deacetylase inhibitor that is known to enhance cellular NER for 
CPD following 24-h pretreatment (Wang et al., 2004).  Optimal inoculum size of 
HeLa cells was 3 x 104 per well and UV-B doses were 1 J/m2 (CPD) and 10 J/m2 
(6-4PP) of UV-C dose equivalents.  In the absence of these inhibitors, HeLa cells 
exhibited faster removal of CPD and 6-4PP compared with primary cutaneous cells 
(Fig. 8 vs Fig. 6), due to lower UV-B doses used.  Upon treatment with MG132, CPD 
and 6-4PP were repaired at slower rates and this inhibition seems more profound in 
6-4PP repair.  In contrast, pretreatment with sodium butyrate slightly enhanced CPD 
repair, consistent with the previous reports.  These results suggest that M-CINUP can 








Screening of chemical library to identify compounds affecting nucleotide excision 
repair activity 
I next tried to identify chemicals that affect cellular NER activity using the 
M-CINUP screening system.  I decided to use HeLa cells and to evaluate the effects 
Figure 8.  Evaluation of the effects of MG132 and sodium butyrate on NER efficiency.  HeLa cells 
were inoculated at 3 x 104 per well in 96-well microplates and pretreated without (open triangles) or with 
10 µM MG132 (closed squares) or DMSO (open squares) for 1 hr, or 5 mM sodium butyrate for 24 hr 
(closed triangles).  The cells were irradiated with UV-B at 1 J/m2 or 10 J/m2 of UV-C dose equivalent 
and analyzed for the repair kinetics of CPD or 6-4PP, respectively.  Each point represents the mean of 
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on 6-4PP repair, which is more rapid compared with CPD repair.  For the screening, a 
chemical library was obtained from RIKEN NPDepo which contains ~24,700 products 
(~9,100 synthesized chemicals, ~7,600 synthesized peptides, ~5,200 natural product 
derivatives and ~2,800 natural products).  After checking that our screening system is 
working using the authentic library with 80 bioactive products, I obtained the pilot 
library containing 376 products which had been selected based on basic structures from 
~24,700 products in RIKEN.  HeLa cells in microplates were pretreated with 
chemicals at 4 or 40 µg/ml for 2 h, and irradiated with UV-B (10 J/m2 of UV-C dose 
equivalent) (Fig. 9).  After 1st screening, I identified 21 compounds showing weak 
effects (1 promotion and 20 inhibition) (data not shown).  I retested the effects of the 
21 compounds using higher concentrations (10 or 50 µg/ml) and longer pretreatment 
periods (12 h) (Fig. 10).  Notably, one compound (#8) showed strong inhibition in a 
dose-dependent manner (Fig. 10A).  Since 9 compounds exhibited cytotoxity and 6 
compounds showed marginal inhibitory effects under this condition, I selected 9 
candidates from the 15 compounds and reanalyzed them at 20 or 80 µg/ml for 4 h.  
As a result, I found two compounds (#7 and #9) showing moderate inhibition activity 





Figure 9.  Schematic representation of the screening system used in this study. 
 
























To confirm the inhibitory effect of compound #8 on 6-4PP repair, I obtained 
a larger amounts of #8 from RIKEN and pretreated HeLa cells with #8 at 50 or 100 
µg/ml for 12 h.  As shown in Fig. 11, the wells treated with compound #8 exhibited a 
high level of fluorescence at 800 nm even after 1- or 2-h repair incubation, confirming 
the strong inhibitory effect.    
 
 
Figure 10.  Second screening of the compounds possibly affecting NER efficiency.  (A) HeLa cells in 
96-well microplates were pretreated with 21 candidate compounds (10 or 50 µg/ml) or DMSO for 12 h.  
The cells were irradiated with UV-B at 10 J/m2 of UV-C dose equivalent and analyzed for the repair kinetics 
of 6-4PP.  (B) For 9 compounds showing marginal activities or cytotoxicity in (A), the cells were pretreated 




































































































































Analysis of structure-activity relationship of compound #8 
 The structure of compound #8 is shown in Fig. 11C and its index name has 
not been assigned.  To analyze the structure-activity relationship of compound #8, I 
obtained 80 kinds of #8 derivatives from RIKEN NPDepo and also purchased 8 
derivatives from chemical companies.  In addition, one related-compound was 
synthesized by Prof. Kunishima’s laboratory.  The chemical structures of major 20 
compounds are shown in Fig. 12.  The strong inhibitory effects were obtained with 
NPD13405, STK887670 and NPD13403 (Fig. 13), and NPD13405 exhibited a higher 
activity than compound #8.  The 3 derivatives have similar structures to #8 and the 
structural differences among them were the substituents of 2-pyranone (4-methyl, 
Figure 11.  Inhibitory effect of compound #8 on 6-4PP repair.  (A and B) HeLa cells in 96-well 
microplates were pretreated with 50 µg/ml (closed diamonds) or 100 µg/ml (closed squares) of compound #8 
or DMSO (open squares) for 12 h and analyzed for the repair kinetics of 6-4PP.  (A) Scanning images at 
700 nm (Sapphire700) and 800 nm (6-4PP) were obtained by the Odyssey infrared imaging system.  (B) 
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3,4-dimethyl, 4-ethyl or 3,4-tetramethylene).  Interestingly, the butyl group or no 
substituent at 4 position loses the inhibitory activity (Fig. 14A).  In addition, the 
(2-methoxyphenyl)methyl group at the nitrogen of the dihydrooxazine also seems 















1.0 1.3 0.95 0.80
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(NPD 4005)
NPD 13405 NPD 13403STK 887670
Figure 13.  Three derivatives of compound #8 exhibiting NER inhibition. 
 
Figure 14.  Structure-activity relationship 









Characterization of the inhibitory effect of NPD13405 on 6-4PP repair 
 To characterize the inhibitory activity of compound #8 and its derivatives in 
more detail, I treated HeLa cells with NPD13405 under various conditions and 
analyzed the repair kinetics of 6-4PP by M-CINUP.  First, the pretreatment of various 
concentrations of NPD13405 (1 - 25 µg/ml) for 12 h exhibitited dose-dependent 
inhibition of 6-4PP repair.  A half-maximal inhibitory concentration (IC50) was ~3.5 
µg/ml at 1-h repair point and ~7.5 µg/ml at 2-h repair point (Fig. 15).  Second, I 
altered the pretreatment time from 0 through 24 h.  The inhibitory effect of 
NPD13405 increased in a time-dependent manner and became plateau over ~8 h at 1-h 
repair point and over ~12 h at 2-h repair point (Fig. 16), indicating that the 
pretreatment for 8 - 12 h is required for its full inhibitory effect.  Third, I examined 
the duration of inhibitory effect of NPD13405.  I pretreated HeLa cells with 20 µg/ml 
of NPD13405 for 12 h and further incubated them for various periods in the absense of 
NPD13405.  The repair ability of 6-4PP in HeLa cells was gradually recovered and 
almost completely after 12-h incubation (Fig. 17).  Finally, I examined whether the 
inhibitory effect of NPD13405 is retained at longer repair periods.  HeLa cells were 
pretreated with NPD13405 at 10 or 20 µg/ml for 12 h and tested for the repair kinetics 
of 6-4PP up to 6 h.  Under this condition, the amounts of 6-4PP in the genome were 
decreased gradually, although with much slower efficiency compared with the control 




















Figure 15.  Repair kinetics of 6-4PP after pretreatment with various concentration of NPD13405.  
HeLa cells in 96-well maicroplates were pretreated with NPD13405 at 1 (closed circles), 5 (triangles), 10 
(diamonds) or 25 µg/ml (squares), or DMSO (open squares) for 12 h and analyzed for the repair kinetics of 
6-4PP.  (A) shows the repair kinetics of 6-4PP.  Each point represents the mean of three independent 
experiments and bars indicate the SD.  (B) The inhibitory effects of NPD13405 at 1- and 2-h repair points were 
calculated from the mean of three experiments. 
Figure 16.  Repair kinetics of 6-4PP after pretreatment with NPD13405 for various periods.  HeLa cells 
in 96-well microplates were pretreated with NPD13405 (10 µg/ml) for 0 (closed circles), 6 (triangles), 12 
(diamonds) or 24 h (squares), or DMSO for 12 h (open squares).  (A) shows the repair kinetics of 6-4PP.  Each 
point represents the mean of three independent experiments and bars indicate the SD.  (B) The inhibitory effects 
























































































































Potentiation of cytotoxic effects of UV and anti-cancer drugs by NPD13405 
pretreatment 
 The ability of NPD13405 to inhibit NER prompted me to examine whether 
NPD13405 enhances the cytotoxic effect of UV as well as anti-cancer drugs producing 
base adducts that can be removed by NER.  For this series of experiments, I used a 
stomach cancer cell line, KKLS, which is transplantable to nude mice and can be also 
applicable to in vivo study.  I firstly investigated the inhibitory effect of NPD13405 
on 6-4PP repair in KKLS cells.  KKLS cells were pretreated with NPD13405 at 50 
µg/ml for 12 h and irradiated with 10 J/m2 of UV-C.  After incubation for 1 or 2 h, 
genomic DNA was isolated and analyzed for 6-4PP repair using a conventional ELISA.  
Figure 17.  Repair kinetics of 6-4PP 
after 12-h pretreatment with NPD13405 
and further incubation without 
NPD13405 for various periods.  HeLa 
cells in 96-well microplates were 
pretreated with DMSO for 12 h (open 
squares), or NPD13405 (20 µg/ml) for 12 
h, further incubated for 0 (closed circles), 
2 (triangles), 4 (diamonds), 12 h (squares) 
in the absense of NPD13405 and analyzed 
for the repair kinetics of 6-4PP.  Each 
point represents the mean of three 
independent experiments and bars indicate 
the SD.   
Figure 18.  Repair kinetics of 6-4PP up to 
6-h repair point after pretreatment with 
NPD13405.  HeLa cells were pretreated 
with 10 µg/ml (closed diamonds) or 20 µg/ml 
(closed squares) of NPD13405 or DMSO 
(open squares) for 12 h and analyzed for the 
repair kinetics of 6-4PP up to 6 h.  Each 
point represents the mean of three 









































The pretreatment with NPD13405 caused striking inhibition of 6-4PP repair (Fig. 19A), 
confirming the inhibitory effect of NPD13405 on NER in KKLS cells as well.  I next 
tested the toxicity of NPD13405 in KKLS cells using a colony formation assay, where 
200 cells were inoculated into 60-mm dishes and incubated for 1 week in the presense 
of various concentrations of NPD13405.  The 50% lethal dose (LD50) of NPD13405 
was ~10 µg/ml and no colonies were observed over 17.5 µg/ml (Fig. 19B).  It should 
be noted that toxicity of NPD13405 was reduced from ~50% to ~65% survival at 10 
µg/ml when NPD13405 was removed after 24-h incubation, leading me to use this 












KKLS cells were pretreated with NPD13405 at 10 µg/ml for 12 h and 
Figure 19.  6-4PP repair kinetics and cytotoxic effect of NPD13405 in stomach cancer cells.  (A) KKLS cells 
were pretreated with NPD13405 (50 µg/ml) (closed squares) or DMSO (open squares) for 12 h, irradiated with 10 J/m2 
of UV-C and analyzed for the repair kinetics of 6-4PP by ELISA.  Each point represents the mean of three independent 
experiments and bars indicate the SD.  (B) KKLS cells were seeded on 60-mm dishes (200 cells/dish) and various 
concentration of NPD13405 was added following 6-h incubation.  The cells were incubated for 7 - 8 days, and colonies 
were counted after fixation and staining with Giemsa solution.  Each point represents the mean of three independent 
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distributed into 60-mm dishes.  Following 6-h incubation in the presense of 
NPD13405, the cells were irradiated with various dose of UV-C and further incubated 
for 7 - 8 days to make colonies.  Importantly, the sensitivity to UV-C irradiation was 
significantly potentiated by NPD13405 (Fig. 20A) and the D37 was 4.5 J/m2 upon 
NPD13405 treatment, whereas 8.5 J/m2 in the absence of NPD13405.  I also checked 
cell cycle distribution following NPD13405 treatment by flow cytometry (Fig. 21).  
The distribution patterns were not significantly altered compared with control sample, 











Figure 20.  Potentiation of cytotoxic effect of UV and cisplatin but not etoposide by NPD13405 pretreatment.  
KKLS cells were pretreated with NPD13405 (10 µg/ml) (closed squares) or DMSO (open squares) for 12 h and 
seeded on 60-mm dishes.  After incubation for 6 h, the cells were irradiated with various doses of UV-C (A) or 
treated with various concentrations of cisplatin for 24 h (B) or etoposide for 6 h (C).  After medium change, cells 
were incubated for 7 - 8 days and colonies were counted as described in the legend of Fig. 19.  Each point 
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I further analyzed the potentiation effect of NPD13405 on cisplatin or 
etoposide sensitivity.  Cisplatin forms mainly intrastrand crosslinks between adjacent 
purines in DNA (~65% 1,2-d(GpG), ~25% 1,2-d(ApG) and ~5 - 10% 1,3-d(GpNpG) 
intrastrand) and also interstrand crosslinks and monofunctional adducts with much less 
efficiency.  The cisplatin-induced intrastrand crosslinks and monoadducts are 
removed by NER, whereas interstrand crosslinks are repaired by crosslink repair 
pathway including NER, translesion synthesis and homologous recombination.  In 
contrast, etoposide inhibits topoisomeraseⅡ and induces DNA double strand breaks 
(DSB) as a consequent.  The cisplatin sensitivity was moderately potentiated by NPD 
13405 (Fig. 20B), while the etoposide sensitivity showed no potentiation and was 
rather slightly reduced (Fig. 20C), suggesting that NPD13405 has no effects on DSB 
repair.  
Figure 21.  Cell cycle distribution after treatment with NPD13405.  KKLS cells were treated with NPD13405 




























Establishment of a microplate-formatted cell-based immunoassay for NER of UV 
photoproduct 
I have newly developed a cell-based immnoassay (M-CINUP), providing a 
rapid approach for the evaluation of NER ability using a smaller number of cells 
compared with ELISA.  In the case of human fibroblasts, I used only 104 cells x 3 
wells (triplicate) = 3 x 104 cells per sample, instead of >106 cells (in a 90-mm plastic 
dish) per sample in ELISA.  In addition, Sapphire700-mediated normalization of cell 
number in each well effectively contributed to more accurate quantification (Fig. 4C).  
Importantly, the repair kinetics of CPD and 6-4PP obtained by M-CINUP showed 
good agreement with that obtained by ELISA (Fig. 5).   
Taking advantage of this assay with a smaller number of cells, I analyzed the 
repair kinetics of CPD and 6-4PP in various primary cells from human skin.  Firstly, 
3 kinds of fibroblasts from newborn and adult donors were tested for NER activity on a 
single plate and were found to exhibit no age-related changes.  This result is 
consistent with the previous observation reported using a host cell reactivation (HCR) 
assay with UV-damaged plasmid (Merkle et al., 2004) and ELISA (Takahashi et al., 
2005), but not with other observation using HCR (Takahashi et al., 2005) and ISBA 
(Goukassian et al., 2000).  Secondly, I compared the repair kinetics of CPD and 
6-4PP in epidermal keratinocytes and melanocytes from newborn donors and showed 
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no significant difference between the two kinds of epidermal cells, consistent with the 
previous report (Schothorst et al., 1991).  Finally, I observed comparable NER 
activity between differentiated and undifferentiated keratinocytes, indicating that 
keratinocyte differentiation has no significant impacts on NER activity at least in vitro.  
The previous study using ISBA supports my data (Oh et al., 2005), whereas conflicting 
results have been reported using a repair replication assay (Liu et al., 1983) and HCR 
(Li et al. 1997).  The various discrepancies among the reports described above might 
be caused by different assay systems employed.  For instance, HCR mainly reflects 
the activity of TCR sub-pathway of NER, while immunoassays such as ELISA and 
ISBA reflect GGR activity.  Other possible factors causing inconsistent results might 
be the differences in cell donors, culture conditions, UV sources (UV-C vs UV-B), UV 
doses and so on.  The newly developed M-CINUP is helpful for reevaluating NER 
activity in various kinds of cutaneous cells under the same conditions.  Furthermore, 
this assay will also enable us to examine NER activity in other organ- and 
tissue-derived primary cells with poor growth activity, which could not be analyzed 
using conventional assays. 
 
Identification of compounds inhibiting NER  
 Another highlight of M-CINUP would be its possible applicability to a high 
throughput screening system.  As shown in Fig. 8, M-CINUP could detect an 
inhibitory or stimulatory effect of MG132 or sodium butyrate, respectively, on cellular 
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NER, suggesting its eligibility to evaluate the chemical compounds affecting NER 
efficiency.  In fact, the screening of the RIKEN NPDepo pilot library containing 376 
compounds identified 3 compounds (#7, 8 and 9) inhibiting NER and no compounds 
enhancing NER.  Compound #8 exhibited stronger activity compared with #7 and 9 
(Fig. 10) and its inhibitory effect on NER was confirmed by ELISA (Fig. 19A).  The 
compound #8 comprised of the pyranobenzoxazine and the (methoxyphenyl)methyl 
group (Fig. 11C) is different from the structures of #7 and 9 (not shown), indicating no 
structural relationship between the three compounds.  In addition, under the condition 
of 12-h pretreatment at 50 µg/ml, #7 and 9, but not #8, showed cytotoxicity, judged by 
cell detachment from microplate’s wells.  I guess that the cellular targets and 
inhibitory mechanisms of the 3 compounds may be different from each other.  For the 
further analysis of compound #7 and 9, I need to identify their derivatives with higher 
activity by screening their structurally related compounds.  In this study, I have 
focused on the analysis of compound #8.   
 
Structure-activity relationship of compound #8 
 I analyzed the activity of 89 derivatives of compound #8 and found that 
NPD13405, STK887670 and NPD13403 exhibit comparable inhibitory effects on NER 
(Fig. 13).  It should be stressed that the activity of NPD13405 was confirmed using 3 
different sources (RIKEN NPDepo, Namiki shoji and Kunishima Lab.) and was 
highest among the related compounds tested so far.  From the careful comparision of 
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major 20 closely related compounds, it was revealed that substituents of a pyranone 
moiety are critical, since the compound with no substituents did not show the 
inhibitory activity (Fig. 14A).  The active compounds possess the 4-methyl, 4-ethyl or 
3,4-dimethyl group.  Importantly, a linear 4-butyl group showed no activity, but a 
butyl group forming a cyclohexene ring by connection to the 3-position (NPD 13403) 
was active.  It would be interesting to test whether a propyl group shows the activity 
or not, although I have not been able to conduct this experiment due to the difficulty of 
obtaining such a compound.  These results suggest that small alkyl group(s) of a 
pyranone ring are required for the activity but a long stretch of alkyl groups interfere 
the activity.  In addition, a (2-methoxyphenyl)methyl group at the nitrogen of the 
dihydrooxazine moiety is also very crucial for the inhibitory activity (Fig. 14B).  In 
particular, the 2-methoxy group appears essential, since a 3-methoxy or 4-methoxy 
group as well as a 2-chloro group showed no activity.  Further studies will be needed 
for understanding the structure-activity relationship in more detail and improving its 
inhibitory activity against NER. 
 
Inhibitory mechanism of NPD13405 
 What is the mechanism of NER inhibition by NPD13405?  What is a 
cellular target of NPD13405?  In this study, unfortunately, I could not have enough 
time to identify a cellular factor that is bound and inhibited by NPD13405.  However, 
I have characterized the inhibitory activity of NPD13405.  As shown in Fig. 18, 
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6-4PP repair was almost completely inhibited at 1-2 h, but recovered at later time 
points (2-6 h), indicating that NPD13405 inhibits 6-4PP repair strongly but not 
completely.   
Fig. 16 shows the interesting observation that the full activity of NPD13405 
is obtained after at least 12-h pre-treatment.  This time course appears to be relatively 
slow.  In the literatures, the pretreatment of MG132 for 1 h is known to inhibit NER, 
whereas sodium butyrate enhances NER after pretreatment for 24 h (Fig. 8).  A 
proteasome inhibitor MG132 has been reported to inhibit UV-induced DDB2 
degradation and hence XPC recruitment to UV-damaged DNA, thereby causing a 
reduction of NER activity (Wang et al., 2005).  On the other hand, sodium butyrate, a 
histone deacetylase inhibitor, is known to increase the GGR activity of CPD in normal 
human cells without affecting UV-induced XPC recruitment to damaged DNA (Wang 
et al., 2004), suggesting that histone deacetylases may regulate not only histones but 
also NER factors.  The requirement of 12 h for maximal inhibition suggests that 
NPD13405 might not be a simple inhibitor to one of core NER factors.  Interestingly, 
NER inhibition by pretreatment of NPD13405 was gradually attenuated when the cells 
were incubated in the absence of NPD13405 before UV-irradiation (Fig. 17), 
indicating that the release from inhibitory effect is also slow.   
I could not examine the effect of NPD13405 on other repair systems in this 
study.  However, NPD13405 did not potentiate etoposide sensitivity in KKLS cells, 
suggesting that NPD13405 may have no effects on DSB repair such as 
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non-homologous end joining and homologous recombination.  To verify this point, I 
need to introduce a comet assay to directly measure DSB and check the impact of 
NPD13405 on their rejoining activity.  In any event, the identification of a cellular 
target of NPD13405 is essential for understanding its inhibitory mechanism.  I am 
currently preparing the experiments of affinity purification using photoaffinity 
linker-coated agarose beads conjugated with the active compound (Kanoh et al., 2003 
& 2005). 
 
Possible applicability of NPD13405 to anti-cancer therapy 
I thought that the NER inhibitory effect of NPD13405 would enhance 
cytotoxic effect of UV or anti-cancer drugs producing NER substrates.  As expected, 
pretreatment of NPD13405 (10 µg/ml, 12 h) potentiated the sensitivity of KKLS cells 
to UV and cisplatin, but not etoposide (Fig. 20), although the potentiation level was not 
so striking (1.7 fold) in cisplatin treatment. Cisplatin is a widely used 
chemotherapeutic drug and produces base adducts consisting of more than 90% 
intrastrand DNA crosslinks, <5% interstrand DNA crosslinks and ~5% monoadducts 
(Jung and Lippard, 2007; Koberle et al., 2011).  Intrastrand DNA crosslinks and 
monoadducts are removed from the genome by NER, whereas interstrand crosslinks 
are repaired by a more complex reactions including NER, translesion synthesis and 
homologous recombination, so called interstrand crosslink repair (ICLR).  Less 
abundant interstrand crosslinks are highly toxic because of their efficient inhibition of 
 42 
DNA replication and transcription.  Since siRNA-mediated downregulation of 
XPF-ERCC1, which is involved in both NER and ICLR, enhances cisplatin sensitivity 
by 4 - 6 fold in non-small cell lung cancer cell lines (Arora et al., 2010), NPD13405 
may not inhibit ICLR.  In addition, as discussed earlier, 6-4PP removal was strongly 
inhibited by NPD13405 at earlier time points, but recovered at later time points (Fig. 
18).  In other words, the incubation periods (2 h) required for complete removal of 
6-4PP was just extended to ~6 h by the pretreatment of NPD13405 (10 µg/ml, 12 h).  
Identification of NPD13405 derivatives with more sustained inhibitory activity is 
needed for the application to anti-cancer therapy, since 2-fold change in IC50 value is 
important for affecting tumor growth in response to cisplatin treatment (Fink et al., 
1997).  One problem in cisplatin treatment is the development of chemoresistance by 
various mechanisms, leading to therapeutic failure.  The new NER inhibitor might be 
helpful especially for sensitizing such cisplatin-resistant cancer cells. 
 
Perspectives 
 I need to identify a cellular target of NPD13405 by affinity purification as 
soon as possible, which hopefully uncovers a new NER player and provides a new 
insight into cellular NER reaction.  In addition, the structure of the target protein may 
help further identifying the derivatives with higher inhibitory activity by an in silico 
docking approach.  For the possible therapeutic application, I have a plan to examine 
whether NPD13405 can potentiate the therapeutic effect of cisplatin treatment using 
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xenograft tumor models with nude mice.  I hope the novel NER inhibitor would 
contribute not only to the elucidation of cellular NER mechanism but also to the 
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